Array BioPharma (ARRY) : During the past 4 weeks, traders have been relatively bearish on Array BioPharma (ARRY), hence the stock is down -5.57% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -22.29% relative to the S&P 500. The 4-week change in the price of the stock is -4.59% and the stock has fallen -22.25% in the past 1 week.
The stock has recorded a 20-day Moving Average of 8.19% and the 50-Day Moving Average is 3.6%. Array BioPharma (NASDAQ:ARRY): stock turned positive on Friday. Though the stock opened at $3.52, the bulls momentum made the stock top out at $3.53 level for the day. The stock recorded a low of $3.43 and closed the trading day at $3.53, in the green by 0.28%. The total traded volume for the day was 1,268,918. The stock had closed at $3.52 in the previous days trading.
The company Insiders own 0.17% of Array BioPharma shares according to the proxy statements. Institutional Investors own 91.09% of Array BioPharma shares. Also, Equity Analysts at the Stifel Nicolaus maintains the rating on Array BioPharma (NASDAQ:ARRY). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $7 per share to $8 per share. The rating by the firm was issued on August 5, 2016.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.